Now, the study by Bonavita et al. shows that complement should be considered a factor of cancer-promoting inflammation in its own right, and identifies the long pentraxin PTX3 as a crucial modulator of the complement-dependent tumor-promoting pathway (3). Here, PTX3 is linked to cancer.